

**MASCC Neurologic Complications Committee
June 22, 2017**

Chair: Charles Loprinzi

Vice Chair: Alex Chan

Attendees:

Name	Email address	Country
Charles Loprinzi	clopinzi@mayo.edu	USA
Frances Boyle	frances.boyle@sydney.edu.au	Australia
Manuel Morales	Mmorales@ull.ej	Spain
Ian Kleckner	Ian_kleckner@umc.rochester.edu	USA
Hiroshi Ishiguro	hishiguromdphdfacp@gmail.com	Japan
Mary Lou Affronti	mary.affronti@duke.edu	USA
Katy Peters	Katharine.peters@duke.edu	USA
Samantha Mayo	Samantha.mayo@utoronto.ca	Canada
Maryam Lustberg	Maryam.lustberg@osumc.edu	USA
Alex Chan	phaac@nus.edu.sg	Singapore
Brenda Shelton	sheltbr@jhmi.edu	USA
Christopher Steer	csteer@bordermedonc.can.au	Australia
Jeong Oi-I	jhoh@mdanderson.org	USA
Eric Roeland	eroeland@ucsd.edu	USA

1. Welcome and Introductions

All of the participants introduced themselves and reported their research/clinical interests. Primary areas of interest were chemotherapy neuropathy and cognitive dysfunction.

2. Areas of interest

There was about 50% of the group that was interested in chemotherapy-induced neuropathy and the other 50% who were interested in cognitive dysfunction troubles. Some of the participants were interested in both of these areas, relatively equally.

3. Potential Neurologic Complication Committee activities

There was discussion with regards to putting together a group manuscript regarding cognitive dysfunction-related issues. More specifically, it was noted that information from geriatric-related cognitive dysfunction and cognitive dysfunction related to dementia issues might relate to chemotherapy-induced cognitive dysfunction. Particularly, tools used to measure cognitive function in each of these situations and interventions to deal with cognitive dysfunction were discussed. Dr. Katie Peters, from Duke, agreed to put together a couple paragraphs and potentially an outline with regards to a manuscript. Other individuals expressed interest in participating in this topic.

Dr. Maryam Lustberg talked about genetic issues related to chemotherapy-induced neuropathy. She noted work that she had been involved with regards to aromatase inhibitor-related evaluations of genetic data. She mentioned that Dr. Steve Sonis had been able to help with ways of looking at data which was different from GWAS. She noted that it would be interesting to look at data that Brian Schneider may have regarding ECOG 5103 and ECOG 1199. While other members of the group did

endorse looking at this, these ECOG data are not from MASCC and it may well be that they are not available to us.

The discussion then turned to potentially putting together a manuscript which would review what is known regarding genetic material to predict CIPN severity in individual patients. Dr. Lustberg noted that she would put together a proposal and/or outline for this project.

4. Subjects for 2018 MASCC annual meeting

There was consensus that it would be nice to propose issues related to neurologic complications for next year's annual MASCC meeting. The following topics were put forward:

- Discussion of gabapentinoids (gabapentin and/or pregabalin) for treatment of chemotherapy peripheral neuropathy was suggested. This could be done either as a single lecture or there could be 2 lectures--one who takes a pro stance and the other who takes a con stance.
- Discussion of the most exciting drugs for treating and/or preventing CIPN, in terms of clinical practice and also in terms of future research.
- Non-drug treatment approaches (e.g. acupuncture, exercise, electrostimulation, biofeedback) for chemotherapy-induced peripheral neuropathy, for clinical practice and for research.
- The best means for measuring CIPN, in practice and in research settings.
- Discussion of the most exciting drugs for treating cognitive function, in terms of clinical practice and in terms of future research.
- Non-drug treatment approaches for cognitive function, for clinical practice and for research.
- The best means for measuring cognitive function in practice and in research settings.

There was interest in potentially having group meetings in between the annual meetings. These could potentially revolve around potential project topics that are discussed above. There was nobody who expressed any opposition to this opportunity.

5. 2018 Workshop

We discussed the pros and cons of having a 2018 workshop prior to the next annual meeting. There were mixed thoughts on this. If we do develop one or more of these research topics and think that we need to have further discussion regarding them, then we could ask for a workshop.